New Preclinical Data for Enanta Oral Coronavirus Protease Inhibitor due October

 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington, DC.

Oral Presentation
Date: Friday, October 21, 2022
Time: 12:15 – 12:45 PM ET
Session Title: Rapid Fire Poster Session: COVID-19 Clinical Issues
Session Location: Walter E. Washington Convention Center, Exhibit Hall BC, Hot Zone Arenas
Presentation Title: “EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients”
Presenter: Li-Juan Jiang, Ph.D.

Poster Presentation
Date: Friday, October 21, 2022
Time: 12:15 – 1:30 PM ET
Session Title: COVID-19: Treatment
Session Location: Walter E. Washington Convention Center, Exhibit Hall BC
Poster #1123: “EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients”
Presenter: Li-Juan Jiang, Ph.D.

Posters will be available to view on the conference platform during the conference. Further information about IDWeek 2022 can be found here.

https://www.biospace.com/article/releases/new-preclinical-data-for-edp-235-enanta-s-oral-coronavirus-protease-inhibitor-designed-for-the-treatment-of-covid-19-to-be-presented-at-idweek-2022/